Diazepanes derivatives useful as LFA inhibitors

Details for Australian Patent Application No. 2004205504 (hide)

Owner Novartis AG

Inventors Oberhauser, Berndt; Meingassner, Gottfried

Agent Davies Collison Cave

Pub. Number AU-B-2004205504

PCT Pub. Number WO2004/065382

Priority 0323976.1 13.10.03 GB; 0301561.7 23.01.03 GB

Filing date 22 January 2004

Wipo publication date 5 August 2004

Acceptance publication date 20 September 2007

International Classifications

C07D 243/08 (2006.01) Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms

C07D 401/06 (2006.01) Heterocyclic compounds containing two or more hetero rings

C07D 401/14 (2006.01) Heterocyclic compounds containing two or more hetero rings

C07D 405/06 (2006.01) Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom

Event Publications

28 July 2005 PCT application entered the National Phase

  PCT publication WO2004/065382 Priority application(s): WO2004/065382

20 September 2007 Application Accepted

  Published as AU-B-2004205504

17 January 2008 Standard Patent Sealed

16 August 2012 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This patent ceased under section 143(a), or Expired. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2004205511-Fixation device

2004205494-Piperazine derivatives and their use as synthesis intermediates